99247-33-3

中文名稱(chēng) 4-苯酰胺-5-二丙氨基-5-氧戊酸鈉鹽

英文名稱(chēng) PROGLUMIDE, SODIUM SALT

CAS 99247-33-3

分子式 C18H27N2NaO4

分子量 358.41

MOL 文件 99247-33-3.mol

99247-33-3 結(jié)構(gòu)式

基本信息物理化學(xué)性質(zhì) 安全數(shù)據(jù) 4-苯酰胺-5-二丙氨基-5-氧戊酸鈉鹽價(jià)格(試劑級(jí)) 常見(jiàn)問(wèn)題列表

基本信息

中文別名

丙谷胺鈉
4-苯酰胺-5-二丙氨基-5-氧戊酸鈉鹽

英文別名

PROGLUMIDE SODIUM
PROGLUMIDE, SODIUM SALT
Proglumide sodium salt solid
4-benzamido-5-(dipropylamino)-5-oxopentanoate
PROGLUMIDE SODIUM SALT SELECTIVE CHOLECY STOK
dl-4-benzamido-n,n-dipropylglutaramicacidsodiumsalt
SODIUM
4-BENZAMIDO-5-(DIPROPYLAMINO)-5-OXOPENTANOATE
4-benzamido-n,n-dipropyl-,sodiumsalt,dl-glutaramicaci
4-BENZOYLAMINO-5-DIPROPYLAMINO-5-OXOPENTANOIC ACID SODIUM
Glutaramic acid, 4-benzamido-N,N-dipropyl-, sodium salt, DL-

物理化學(xué)性質(zhì)

儲(chǔ)存條件Desiccate at RT

溶解度H₂O: soluble

溶解度可溶于水中

形態(tài)solid

顏色white

水溶解性溶于水至100mM

InChI1S/C18H26N2O4.Na/c1-3-12-20(13-4-2)18(24)15(10-11-16(21)22)19-17(23)14-8-6-5-7-9-14;/h5-9,15H,3-4,10-13H2,1-2H3,(H,19,23)(H,21,22);/q;+1/p-1

InChIKeyUFMWGCINVOIJSO-UHFFFAOYSA-M

SMILES[Na+].CCCN(CCC)C(=O)C(CCC([O-])=O)NC(=O)c1ccccc1

安全數(shù)據(jù)

WGK Germany3

存儲(chǔ)類(lèi)別11 - Combustible Solids

4-苯酰胺-5-二丙氨基-5-氧戊酸鈉鹽價(jià)格(試劑級(jí))

報(bào)價(jià)日期	產(chǎn)品編號(hào)	產(chǎn)品名稱(chēng)	CAS號(hào)	包裝	價(jià)格
2026/06/05	HY-103354R	4-苯酰胺-5-二丙氨基-5-氧戊酸鈉鹽 Proglumide sodium (Standard)	99247-33-3	5 mg	416元
2026/06/05	HY-103354R	4-苯酰胺-5-二丙氨基-5-氧戊酸鈉鹽 Proglumide sodium (Standard)	99247-33-3	10 mg	672元
2026/06/05	HY-103354R	4-苯酰胺-5-二丙氨基-5-氧戊酸鈉鹽 Proglumide sodium (Standard)	99247-33-3	25 mg	1344元

常見(jiàn)問(wèn)題列表

生物活性

Proglumide sodium 是一種非肽和口服活性膽囊收縮素 (CCK)-A/B 受體拮抗劑。Proglumide sodium 選擇性阻斷 CCK 在中樞神經(jīng)系統(tǒng)中的作用。Proglumide sodium 具有抑制胃分泌和保護(hù)胃十二指腸粘膜的能力，還具有抗癲癇和抗氧化活性。

靶點(diǎn)

Cholecystokinin (CCK)-A/B receptors

體外研究

In an in vitro study, Proglumide at concentrations between 0.3-10 mM inhibits CCK-stimulated amylase release dose-dependently, while Proglumide does not influence the basal amylase release at concentrations between 0-3 mM. Dose-response curves to CCK for amylase release shifted to the right with increase in Proglumide concentration. This inhibition by Proglumide is reversible. In addition, the effect of Proglumide is selective for CCK and its related peptide.
The incubation of HT29 cells with Proglumide significantly reduces the [ ³ H]-thymidine incorporation to HT29 cells in a dose-dependent manner, with an IC ₅₀ of 6.5 mM. Proglumide reduces in a dose-dependent manner the percentage of necrosis with a parallel increase of apoptosis up to 70%.

體內(nèi)研究

Proglumide (250-750?mg/kg; intraperitoneal injection; adult male Sprague Dawley rats) treatment is significantly effective in ameliorating the seizure activities, cognitive dysfunctions, and cerebral oxidative stress.